NCT06426368Not yet recruiting
Soluble ST2 in Patients With Heart Failure"
" Prognostic Value of Soluble ST2 Beyond B-Type Natriuretic Peptide in Management of Patients With Heart Failure"
Source: ClinicalTrials.gov · Last updated 23 May 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
1. The aim of this study was to explore the relationship between peripheral circulating serum soluble suppression of tumorigenicity-2 (sST2) levels and inflammatory biomarkers in patients with heart failure 2. Additive role of sST2 to NPs in of heart failure patients
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 12 May 2024
- Start date
- 1 Jul 2024
- Primary completion date
- 1 Jul 2026
- Lead sponsor
- Assiut University
- Diseases
- Heart failure
- NCT number
- NCT06426368
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Jul 2024 to the primary completion date, 1 Jul 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with Acute coronary syndrome within 30 days.
- chronic kidney disease patients with glomerular filtration rate \< 30
Age
- Patients \<18 years
Other
- Patients with documented evidence of cardiogenic shock .
- Patients with interstitial pulmonary fibrosis .
Who the study is looking for
- patients 18-80 years.
- Both sexes will be included.
- including signs and symptoms of HF (e.g., elevated jugular venous pressure and altered apical beat position), altered LVEF (\< 40%; 40%-49%; ≥ 50%)
Age in the registry: 18 years to 80 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.